<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="205633">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411866</url>
  </required_header>
  <id_info>
    <org_study_id>NAA105416</org_study_id>
    <nct_id>NCT00411866</nct_id>
  </id_info>
  <brief_title>Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812</brief_title>
  <official_title>Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole 400mg on Pharmacokinetics of SB-773812 20mg.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine if there is a difference in how SB-773812 is
      distributed through the bloodstream before and after multiple doses of ketoconazole have
      been given and to determine if there is a difference in how safe and well tolerated
      SB-773812 is when given on its own and given with ketoconazole.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood sampling over period of 336 hours post dosing with SB-773812</measure>
    <time_frame>over period of 336 hours post dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: ECG, vital signs, adverse events, clinical labs over 48 hours post SB-773812 dosing.</measure>
    <time_frame>over 48 hours post SB-773812 dosing.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB773812</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <other_name>SB773812</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy

          -  Body Weight &gt;/=50kg and BMI 18.5-29.9 kg/m2 inclusive

          -  Normal 12-lead ECG, physical examination and lab screen

        Exclusion criteria:

          -  A history of psychiatric illness,

          -  A history or presence gastro-intestinal,

          -  A hepatic or renal disease or orthostatic hypotension.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dundee</city>
        <state>Forfarshire</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>March 15, 2012</lastchanged_date>
  <firstreceived_date>December 13, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
